Cochrane invites prospective authors to propose new Cochrane Reviews by submitting a proposal in Editorial Manager. Please see the Cochrane Library information for authors for further details.

A new chapter for Cochrane
Cochrane has embarked on an important change programme to transform the way we produce the high-quality, independent and timely evidence. The new model is designed to ensure Cochrane remains viable, sustainable, and focused on the greatest global health and care challenges now and into the future. As part of the new model we are implementing a Central Editorial Service to streamline the editorial process.
We are very grateful to everyone who contributes their time and expertise to Cochrane Lung Cancer Group. We encourage you to look out for further communications about Cochrane's plans for the future and new opportunities to get involved. You can stay connected by:

• Following Cochrane on your favourite social media platform
• Opting in to Cochrane email communications in your Cochrane Account

We expect any new team to include at least one leading author previously involved in all steps of a fully published Cochrane Review, someone with methodological and statistical expertise and someone who is demonstrably fluent in writing English.

Here is a list of available titles but feel free to suggest others....

- Radical radiotherapy for stage I / II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable)

- Anti-angiogenics for malignant pleural mesothelioma

- Thoracic radiotherapy for extensive-stage small cell lung cancer

- Cisplatin + etoposide versus other platinum based regimens for people with extensive small cell lung cancer

- Mini-invasive procedures for the staging of NSCLC (DTA review)

- Addition of anti-angiogenic therapy to first line chemotherapy for advanced non-small cell lung cancer